6ix — Find Your Next Investment

Discover investor relations events, company profiles, and opportunities on 6ix. Connect with public companies and attend live investor events.

Please enable JavaScript to use all features of 6ix.com.

Originaltext

Diese Übersetzung bewerten

Mit deinem Feedback können wir Google Übersetzer weiter verbessern

Latest Press Releases

Time	Headline
7m ago	Parvis Signs Binding Letter of Intent to Acquire FavorPoint Capital, a U.S. FINRA-Registered Broker-Dealer, Expanding into American Private Markets
8m ago	Kelun-Biotech Announces Phase III Trial of Sacituzumab Tirumotecan (sac-TMT) versus Chemotherapy as First‑line Treatment for Advanced TNBC Met Primary Endpoint of PFS
8m ago	Free People to Open New free-est Store in Stone Harbor, NJ on May 22, 2026
10m ago	Metals Australia Limited Announces Participation in THE Mining Investment Event, Quebec City, June 2-4, 2026
11m ago	CirTran Corporation Achieves Profitability in First Quarter 2026: Revenue Soars 152%, Company Swings to $2.2 Million Net Income

About

2,981.00JPY-54.00 -1.78%

Closed • Updated at 14:46 GMT+00:00

Market Cap$16.80B

P/E Ratio12.37

Volume2.21M

Beta0.56

RSI34.71

Gross Margin82.28%

Health TechnologyPharmaceuticals: Major

Shionogi & Co., Ltd. — investor relations, events, news, and company updates on 6ix.

Latest News

Shionogi Receives Contract with U.S. Government Through BARDA's Project BioShield to Enhance National Preparedness for Drug-Resistant Bacterial Threats

ESCMID Global 2026: Shionogi Presents New Real-World Data Highlighting Clinical Effectiveness of Fetroja®/Fetcroja® (cefiderocol) in MBL-Producing Enterobacterales Infections

Shionogi Completes Acquisition of All Rights to RADICAVA (edaravone)

Apnimed Announces Strategic Monetization of Shionogi-Apnimed Sleep Science (SASS) Joint Venture Stake for $150M and Royalties, Strengthening Focus on its Wholly-Owned OSA Program, AD109

BioVersys Reports Corporate Highlights and Financial Results for the Full Year 2025

Community Chat

Ask AI